Central Pharmaceutical JSC No3
VN:DP3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (10.8), the stock would be worth ₫121 762.41 (110% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.2 | ₫58 100 |
0%
|
| 3-Year Average | 10.8 | ₫121 762.41 |
+110%
|
| 5-Year Average | 10.2 | ₫114 841.25 |
+98%
|
| Industry Average | 39.4 | ₫443 706.03 |
+664%
|
| Country Average | 9.4 | ₫106 344.67 |
+83%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| VN |
C
|
Central Pharmaceutical JSC No3
VN:DP3
|
1.2T VND | 5.2 | 8.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 49.7 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 22.3 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 19.7 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 14.3 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 16.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.7 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 13.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.3 | 16.8 |
Market Distribution
| Min | 0.7 |
| 30th Percentile | 5.9 |
| Median | 9.4 |
| 70th Percentile | 15.7 |
| Max | 1 545 |
Other Multiples
Central Pharmaceutical JSC No3
Glance View
Central Pharmaceutical JSC No.3 engages in the manufacture and sale of pharmaceutical, cosmetic, and nutritious food. The company is headquartered in Haiphong, Hai Phong. The company went IPO on 2015-07-17. The firm's leading products include botanical medicine and other types of drugs, health supplements and cosmetics, among others. Besides, the Company partakes in the commerce of medical equipment and supplies, as well as the conduct of medical research.
